Blurbs

Robert W. Baird Thinks Atreca’s Stock is Going to Recover

In a report issued on June 1, Joel Beatty from Robert W. Baird maintained a Buy rating on Atreca (BCELResearch Report), with a price target of $9.00. The company’s shares closed last Thursday at $1.56, close to its 52-week low of $1.52.

According to TipRanks.com, Beatty is a 1-star analyst with an average return of -1.1% and a 41.0% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Atreca is a Strong Buy with an average price target of $17.40, implying a 1001.3% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Atreca’s market cap is currently $61.36M and has a P/E ratio of -0.55.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.

Read More on BCEL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos